CD274 and non-small cell lung carcinoma: These results altogether suggest that TMB would strongly complement PD-L1 expression assessment and may eventually help physicians rule in the most personalized therapeutic approach based on single-agent or combination ICIs in the first-line management of advanced non-oncogene-addicted NSCLC.